Her-2/neu as Predictive Marker for Endocrine Therapy and Chemotherapy in Patients with Metastatic Breast Cancer

By Köstler Wolfgang J.   Zielinski Christoph C.  

Breast Cancer Research and Treatment, Vol. 81, Iss. 1, 2003-01 ,pp. : 73-84

Springer Publishing Company

Access to resources Recommend Favorite

Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer

By Gillogly Michael   Kallinteris Nikoletta   Xu Minzhen   Gulfo Joseph   Humphreys Robert   Murray James  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 6, 2004-06 ,pp. : 490-496

Springer Publishing Company

Access to resources Recommend Favorite

The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer

By  

The Women's Oncology Review, Vol. 4, Iss. 2, 2004-06 ,pp. : 139-140

Informa Healthcare

Access to resources Recommend Favorite

HER-2/Neu overexpression does not predict response to neoadjuvant chemotherapy or prognosticate survival in patients with locally advanced breast cancer

By Tulbah Asma   Ibrahim Ezzeldin   Ezzat Adnan   Ajarim Dahish   Rahal Mohammed   Weshi Amr   Sorbris Ralph  

Medical Oncology, Vol. 19, Iss. 1, 2002-03 ,pp. : 15-23

Humana Press, Inc

Access to resources Recommend Favorite

HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy

By Falo Catalina   Moreno Abelardo   Varela Mar   Lloveras Belen   Figueras Agnès   Escobedo Agustín  

Journal of Cancer Research and Clinical Oncology, Vol. 133, Iss. 7, 2007-07 ,pp. : 423-429

Springer Publishing Company

Access to resources Recommend Favorite